This series of live workshops will cover the importance of LAG-3 as a new immunotherapy target and the emerging data on the mechanism of action, use, and safety of anti–LAG-3 immunotherapies across a range of malignancies. Accompanying these workshops will be a downloadable slideset, simulcasts, an expert commentary, a PDF practice resource, and an on-demand webcast.
Live webinars!
Webinar 1 - June 28, 2022
Webinar 2 - July 6, 2022
Webinar 3 - July 19, 2022
Watch this on-demand webcast of a live webinar to gain expert insights on the safety and efficacy of anti–LAG-3 immunotherapies in the management of various solid tumors.
In this commentary, Dr. Evan Lipson reviews LAG-3 as a therapeutic target and discusses evidence from the RELATIVITY-047 trial of the combination of the anti–LAG-3 antibody relatlimab plus nivolumab as first-line therapy in advanced melanoma.
Download these slides from a live workshop series to learn more about LAG-3 as the latest validated immune checkpoint therapeutic target, evidence on the first approved LAG-3 therapy, relatlimab, and the many investigational agents targeting LAG-3 across multiple tumor types.
Download these slides explaining the mechanism of action of LAG-3.
Download this PDF summary resource to learn more about LAG-3 as the latest validated immune checkpoint therapeutic target, the first approved LAG-3 therapy relatlimab, and investigational agents targeting LAG-3 across multiple tumor types.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.